Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Enhancing viral vaccine production using engineered knockout vero cell lines - A second look.

Hoeksema F, Karpilow J, Luitjens A, Lagerwerf F, Havenga M, Groothuizen M, Gillissen G, Lemckert AAC, Jiang B, Tripp RA, Yallop C.

Vaccine. 2018 Apr 12;36(16):2093-2103. doi: 10.1016/j.vaccine.2018.03.010. Epub 2018 Mar 16.

2.

Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56.

Duffy MR, Alonso-Padilla J, John L, Chandra N, Khan S, Ballmann MZ, Lipiec A, Heemskerk E, Custers J, Arnberg N, Havenga M, Baker AH, Lemckert A.

J Gen Virol. 2018 Jan;99(1):135-147. doi: 10.1099/jgv.0.000978. Epub 2017 Nov 20.

PMID:
29154744
3.

Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.

Alonso-Padilla J, Papp T, Kaján GL, Benkő M, Havenga M, Lemckert A, Harrach B, Baker AH.

Mol Ther. 2016 Feb;24(1):6-16. doi: 10.1038/mt.2015.194. Epub 2015 Oct 19. Review.

4.

Challenges in manufacturing adenoviral vectors for global vaccine product deployment.

Vellinga J, Smith JP, Lipiec A, Majhen D, Lemckert A, van Ooij M, Ives P, Yallop C, Custers J, Havenga M.

Hum Gene Ther. 2014 Apr;25(4):318-27. doi: 10.1089/hum.2014.007. Epub 2014 Apr 2. Review.

PMID:
24593243
5.

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.

Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J.

Clin Vaccine Immunol. 2010 Nov;17(11):1687-94. doi: 10.1128/CVI.00311-10. Epub 2010 Sep 8. Erratum in: Clin Vaccine Immunol. 2011 Feb;18(2):353.

6.

Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects.

Radosević K, Rodriguez A, Lemckert A, Goudsmit J.

Expert Rev Vaccines. 2009 May;8(5):577-92. doi: 10.1586/erv.09.14. Review.

PMID:
19397415
7.

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.

Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH.

J Virol. 2008 May;82(10):4844-52. doi: 10.1128/JVI.02616-07. Epub 2008 Mar 12.

8.

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.

Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2007 May;81(9):4654-63. Epub 2007 Feb 28.

9.

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.

Thorner AR, Lemckert AA, Goudsmit J, Lynch DM, Ewald BA, Denholtz M, Havenga MJ, Barouch DH.

J Virol. 2006 Dec;80(24):12009-16. Epub 2006 Oct 11.

10.

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.

Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, Abbink P, Nanda A, Swanson PE, Bates AT, O'Brien KL, Havenga MJ, Goudsmit J, Barouch DH.

J Clin Microbiol. 2006 Oct;44(10):3781-3.

11.

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity.

Lemckert AA, Grimbergen J, Smits S, Hartkoorn E, Holterman L, Berkhout B, Barouch DH, Vogels R, Quax P, Goudsmit J, Havenga MJ.

J Gen Virol. 2006 Oct;87(Pt 10):2891-9.

PMID:
16963747
12.

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.

Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J.

J Gen Virol. 2006 Aug;87(Pt 8):2135-43.

PMID:
16847108
13.

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH.

Nature. 2006 May 11;441(7090):239-43. Epub 2006 Apr 16.

PMID:
16625206
14.

Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers.

Lecollinet S, Gavard F, Havenga MJ, Spiller OB, Lemckert A, Goudsmit J, Eloit M, Richardson J.

J Virol. 2006 Mar;80(6):2747-59.

15.

Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.

Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH.

J Virol. 2005 Nov;79(22):14161-8.

16.

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2005 Aug;79(15):9694-701.

17.

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.

Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH.

J Immunol. 2005 Jun 1;174(11):7179-85.

18.

The dendritic cell-derived protein DC-STAMP is highly conserved and localizes to the endoplasmic reticulum.

Eleveld-Trancikova D, Triantis V, Moulin V, Looman MW, Wijers M, Fransen JA, Lemckert AA, Havenga MJ, Figdor CG, Janssen RA, Adema GJ.

J Leukoc Biol. 2005 Mar;77(3):337-43. Epub 2004 Dec 15.

PMID:
15601667
19.

Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, Verhaagh S, Custers J, Zuijdgeest D, Berkhout B, Bakker M, Quax P, Goudsmit J, Havenga M.

J Virol. 2004 Dec;78(23):13207-15.

20.

Challenges in the search for an HIV vaccine.

Lemckert AA, Goudsmit J, Barouch DH.

Eur J Epidemiol. 2004;19(6):513-6. Review.

PMID:
15330122
21.

Adenovirus fibre exchange alters cell tropism in vitro but not transgene-specific T CD8+ immune responses in vivo.

Mercier S, Verhaagh S, Goudsmit J, Lemckert A, Monteil M, Havenga M, Eloit M.

J Gen Virol. 2004 May;85(Pt 5):1227-36.

PMID:
15105539
22.

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M.

J Virol. 2003 Aug;77(15):8263-71.

23.

Genetic heterogeneity in response to adenovirus gene therapy.

Lefesvre P, Attema J, Lemckert A, Havenga M, van Bekkum D.

BMC Mol Biol. 2003 Apr 5;4:4. Epub 2003 Apr 5.

24.

Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD, Uytdehaag F, Quax PH, Logtenberg T, Mehtali M, Bout A.

J Virol. 2002 May;76(9):4612-20.

25.

Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B.

Knaän-Shanzer S, Van Der Velde I, Havenga MJ, Lemckert AA, De Vries AA, Valerio D.

Hum Gene Ther. 2001 Nov 1;12(16):1989-2005. Erratum in: Hum Gene Ther. 2003 Aug 10;14(12):1214.

PMID:
11686940
26.

Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.

Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R.

J Immunol. 2001 Apr 15;166(8):5236-44.

27.

Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber.

Goossens PH, Havenga MJ, Pieterman E, Lemckert AA, Breedveld FC, Bout A, Huizinga TW.

Arthritis Rheum. 2001 Mar;44(3):570-7.

28.

Improved adenovirus vectors for infection of cardiovascular tissues.

Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, Valerio D, Bout A, Quax PH.

J Virol. 2001 Apr;75(7):3335-42. Erratum in: J Virol 2001 Jun;75(11):5440.

Supplemental Content

Loading ...
Support Center